Literature DB >> 31377280

Effects of Immersive Virtual Reality Headset Viewing on Young Children: Visuomotor Function, Postural Stability, and Motion Sickness.

Lawrence Tychsen1, Paul Foeller2.   

Abstract

PURPOSE: To assess the safety of VR 3D headset (virtual reality 3-dimensional binocular-stereoscopic near-eye display) use in young children. Product safety warnings that accompany VR headsets ban their use in children under age 13 years.
DESIGN: Prospective, interventional, before-and-after study.
METHODS: Recordings were obtained in 50 children (29 boys) aged 4-10 years (mean 7.2 ± 1.8 years). Minimum binocular corrected distance visual acuity (CDVA) was 20/50 (logarithm of the minimum angle of resolution [logMAR] 0.4) and stereoacuity 800 seconds of an arc or better. A Sony PlayStation VR headset was worn for 2 sequential play sessions (of 30 minutes each) of a first-person 3D flying game (Eagle Flight) requiring head movement to control flight direction (pitch, yaw, and roll axes). Baseline testing preceded VR exposure, and each VR session was followed by post-VR testing of binocular CDVA, refractive error, binocular eye alignment (strabismus), stereoacuity, and postural stability (imbalance). Visually induced motion sickness was probed using the Simulator Sickness Questionnaire modified for pediatric use (Peds SSQ). Visual-vestibulo-ocular reflex (V-VOR) adaptation was also tested pre- vs post-trial in 5 of the children. Safety was gauged as a decline or change from baseline in any visuomotor measure.
RESULTS: Forty-six of 50 children (94%) completed both VR play sessions with no significant change from baseline in measures of binocular CDVA (P = .89), refractive error (P = .36), binocular eye alignment (P = .90), or stereoacuity (P = .45). Postural stability degraded an average 9% from baseline after 60 minutes of VR exposure (P = .06). Peds SSQ scores increased a mean 4.7%-comparing pretrial to post-trial-for each of 4 symptom categories: eye discomfort (P = .02), head/neck discomfort (P = .03), fatigue (P = .03), and motion sickness (P = .01). None of the children who finished both trial sessions (94%) asked to end the play, and the majority were disappointed when play was halted. V-VOR gain remained unaltered in the 5 children tested. Three children (6% of participants) discontinued the trial during the first 10 minutes of the first session of VR play, 2 girls (aged 5 and 6 years) and 1 boy (aged 7 years). The girls reported discomfort consistent with mild motion sickness; the boy said he was bored and the headset was uncomfortable. No child manifested aftereffects ("flashbacks") in the days following the VR exposure.
CONCLUSION: Young children tolerate fully immersive 3D virtual reality game play without noteworthy effects on visuomotor functions. VR play did not induce significant post-VR postural instability or maladaption of the vestibulo-ocular reflex. The prevalence of discomfort and aftereffects may be less than that reported for adults.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31377280     DOI: 10.1016/j.ajo.2019.07.020

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

1.  Developing an Immersive Virtual Reality Training System for Novel Pediatric Power Wheelchair Users: Protocol for a Feasibility Study.

Authors:  Sara Drisdelle; Liam Power; Scott Thieu; Jordan Sheriko
Journal:  JMIR Res Protoc       Date:  2022-10-06

2.  Virtual Reality for Distraction and Relaxation in a Pediatric Hospital Setting: An Interventional Study With a Mixed-Methods Design.

Authors:  Sylvie Bernaerts; Bert Bonroy; Jo Daems; Romy Sels; Dieter Struyf; Inge Gies; Wessel van de Veerdonk
Journal:  Front Digit Health       Date:  2022-05-31

3.  Clinical predictors of cybersickness in virtual reality (VR) among highly stressed people.

Authors:  Hyewon Kim; Dong Jun Kim; Won Ho Chung; Kyung-Ah Park; James D K Kim; Dowan Kim; Kiwon Kim; Hong Jin Jeon
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

4.  Feasibility and tolerability of ophthalmic virtual reality as a medical communication tool in children and young people.

Authors:  Peter M Maloca; Emily A Williams; Faisal Mushtaq; Andreas Rueppel; Philipp L Müller; Clemens Lange; Emanuel R de Carvalho; Nadja Inglin; Michael Reich; Catherine Egan; Pascal W Hasler; Adnan Tufail; Hendrik P N Scholl; Philippe C Cattin
Journal:  Acta Ophthalmol       Date:  2021-05-14       Impact factor: 3.988

Review 5.  Concern of Photosensitive Seizures Evoked by 3D Video Displays or Virtual Reality Headsets in Children: Current Perspective.

Authors:  Lawrence Tychsen; Liu Lin Thio
Journal:  Eye Brain       Date:  2020-02-11

Review 6.  Interpersonal Affective Touch in a Virtual World: Feeling the Social Presence of Others to Overcome Loneliness.

Authors:  Letizia Della Longa; Irene Valori; Teresa Farroni
Journal:  Front Psychol       Date:  2022-01-11

7.  Immersive Virtual Reality in Alleviating Pain and Anxiety in Children During Immunization in Primary Care: A Pilot Randomized Controlled Trial.

Authors:  Zi Ying Chang; Gary Chun-Yun Kang; Eileen Yi Ling Koh; Rodney Jin Kai Fong; Jiasheng Tang; Chi Keong Goh; Ngiap Chuan Tan
Journal:  Front Pediatr       Date:  2022-03-25       Impact factor: 3.418

8.  Virtual Reality in the Pediatric Intensive Care Unit: Patient Emotional and Physiologic Responses.

Authors:  Colleen M Badke; Sheila Krogh-Jespersen; Rachel M Flynn; Avani Shukla; Bonnie S Essner; Marcelo R Malakooti
Journal:  Front Digit Health       Date:  2022-03-28

Review 9.  Virtual Reality and Augmented Reality in Ophthalmology: A Contemporary Prospective.

Authors:  Mina Iskander; Titilola Ogunsola; Rithambara Ramachandran; Richard McGowan; Lama A Al-Aswad
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2021 May-Jun 01

10.  Could virtual reality applications pose real risks to children and adolescents? A systematic review of ethical issues and concerns.

Authors:  Polyxeni Kaimara; Andreas Oikonomou; Ioannis Deliyannis
Journal:  Virtual Real       Date:  2021-08-03       Impact factor: 4.697

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.